Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We would like to congratulate Dr Audrey Gérard on her three-year Biotechnology and Biological Sciences Research Council (BBSRC) New Investigator Award. The award will allow Audrey to examine how the behaviour of killer T cells is coordinated to optimise immunity against pathogens and tumour growth.

Dr Audrey Gérard in her lab at the Kennedy Institute.

Killer CD8 T cells attack infected or mutated cells to protect against pathogens and tumour growth. There are many different CD8 T cell clones in the body – only a fraction of these recognise the same target and the amount of protection offered by each clone varies.

Audrey's group uses state-of-the-art imaging approaches to understand how CD8 T cell clones talk to each other during an immune response. Their work will determine how different clones coordinate their activity to rapidly clear infection and establish long-term immunity, while limiting damage to the body's own tissues. This information may guide the development of better vaccines, such as against influenza infection.

"This award is an amazing opportunity for me to tackle this project, which aims to study how CD8 T cells organise themselves as an ecosystem during healthy responses. I believe it will give a different perspective on our understanding of immune response coordination and regulation", said Dr Gérard.

Director of Research at the Kennedy Institute, Professor Michael Dustin, said: "This award recognises Audrey's fundamental work in immunobiology, laying the foundation for future cures."

Audrey joined the Kennedy Institute in 2016 as a Senior Research Fellow funded by the Kennedy Trust for Rheumatology Research.

Funding

BBSRC logo

 

 

 

Similar stories

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Ten Years of Athena Swan in the Medical Sciences Division

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.

Oxford's largest ever study into varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications, establishes for the first time a critical genetic risk score to predict the likelihood of patients suffering with varicose veins to require surgery, as well as pointing the way towards potential new therapies.

Reflecting on the role of Clinical Director of Trauma and Orthopaedics

In 2021 Professor Andrew Price was appointed Clinical Director of Trauma and Orthopaedics at the Oxford University Hospitals NHS Foundation Trust. After 9 months in post, we find out what the challenges are and what he’s been able to bring to the role.

Building a humanoid bioreactor

A humanoid robot is being used at NDORMS in an attempt to grow tendon tissue for repairing shoulder injuries.